ConductScience.org, home

Paper33859820

Effects of obesity and 10 weeks metformin treatment on liver steatosis.

Hakkak R and 4 others. Biomed Rep, 2021. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Effects of obesity and 10 weeks metformin treatment on liver steatosis. Papers, record 33859820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33859820

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of obesity and 10 weeks metformin treatment on liver steatosis.
PubMed
Journal
Biomed Rep
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.39
iCite
Revised in PubMed
2025-08-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hakkak RReza
2Rose SShannon
3Spray BBeverly
4Kozaczek MMelisa
5Korourian SSoheila

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P20 GM109096NIGMS NIH HHSUnited StatesP20GM109096PubMed

Source NIH RePORTER

Download CSV of grants

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118492523Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.J Pediatr2008https://conductscience.org/library/papers/18492523PubMed
232155673A novel metformin derivative showed improvement of lipid metabolism in obese rats with type 2 diabetes.Clin Exp Pharmacol Physiol2020https://conductscience.org/library/papers/32155673PubMed
318556965Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial.J Pediatr Endocrinol Metab2008https://conductscience.org/library/papers/18556965PubMed
420124139Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.Arch Pediatr Adolesc Med2010https://conductscience.org/library/papers/20124139PubMed
528052534Metformin; a review of its history and future: from lilac to longevity.Pediatr Diabetes2017https://conductscience.org/library/papers/28052534PubMed
617402991GI epidemiology: nonalcoholic fatty liver disease.Aliment Pharmacol Ther2007https://conductscience.org/library/papers/17402991PubMed
731749893Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats.Diabetol Metab Syndr2019https://conductscience.org/library/papers/31749893PubMed
810048159Diet and risk of ethanol-induced hepatotoxicity: carbohydrate-fat relationships in rats.Toxicol Sci1999https://conductscience.org/library/papers/10048159PubMed
910973319Metformin reverses fatty liver disease in obese, leptin-deficient mice.Nat Med2000https://conductscience.org/library/papers/10973319PubMed
1030038219Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo.Nat Med2018https://conductscience.org/library/papers/30038219PubMed
1111567710Metformin in non-alcoholic steatohepatitis.Lancet2001https://conductscience.org/library/papers/11567710PubMed
125016304Fat mobilization in vitro and in vivo in the genetically obese Zucker rat "fatty".J Lipid Res1972https://conductscience.org/library/papers/5016304PubMed
1315277403Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.Diabetes2004https://conductscience.org/library/papers/15277403PubMed
1423084707Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010.J Pediatr2013https://conductscience.org/library/papers/23084707PubMed
1525210757Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome.J Pediatr Endocrinol Metab2015https://conductscience.org/library/papers/25210757PubMed
1622528625Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors.Genes Nutr2012https://conductscience.org/library/papers/22528625PubMed
1729757972Short-Term Soy Protein Isolate Feeding Prevents Liver Steatosis and Reduces Serum ALT and AST Levels in Obese Female Zucker Rats.Biomedicines2018https://conductscience.org/library/papers/29757972PubMed
1825676019Metformin and metabolic diseases: a focus on hepatic aspects.Front Med2015https://conductscience.org/library/papers/25676019PubMed
1920071470Prevalence of high body mass index in US children and adolescents, 2007-2008.JAMA2010https://conductscience.org/library/papers/20071470PubMed
2026186426Short- and Long-Term Soy Diet Versus Casein Protects Liver Steatosis Independent of the Arginine Content.J Med Food2015https://conductscience.org/library/papers/26186426PubMed

See all 33 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42451064Impaired Renal Mitochondria and Bioenergetics During Obesity-Associated NAFLD.Nutrients2026https://conductscience.org/library/papers/42451064PubMed
40647220Obesity-Associated NAFLD Coexists with a Chronic Inflammatory Kidney Condition That Is Partially Mitigated by Short-Term Oral Metformin.Nutrients2025https://conductscience.org/library/papers/40647220PubMed
37627299Effect of Metformin Treatment on Serum Metabolic Profile Changes in Lean and Obese Zucker Rat Model for Fatty Liver Disease.Biomolecules2023https://conductscience.org/library/papers/37627299PubMed
37271372Hepatic insulin receptor: new views on the mechanisms of liver disease.Metabolism2023https://conductscience.org/library/papers/37271372PubMed
35432282Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model.Front Microbiol2022https://conductscience.org/library/papers/35432282PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
LEP3952PubTator's text mininghttps://conductscience.org/library/genes/3952NCBI Gene
PTGS25743PubTator's text mininghttps://conductscience.org/library/genes/5743NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33859820

GET https://conductscience.org/api/papers/v1/33859820/references?page=2